Aavocyte - About the company
Aavocyte is an unfunded company based in Seattle (United States), founded in 2019. It operates as a Developer of immunotherapeutics for cancer treatment. Aavocyte has not raised any funding yet. The company has 3359 active competitors, including 1144 funded and 801 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of immunotherapeutics for cancer treatment. The company offers T cell immune therapy products to treat cancers based on the proprietary technology targeting the rAAV delivery platform.
Key Metrics
Founded Year
2019
Location
Seattle, United States
Stage
Unfunded
Ranked
2606th among 3359 active competitors
Similar Companies
Sign up to download Aavocyte's company profile
Aavocyte's funding and investors
Aavocyte has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Aavocyte's Competitors and alternates
Top competitors of Aavocyte include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Aavocyte, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 73/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
2606th |  Aavocyte 2019, Seattle (United States), Unfunded | Developer of immunotherapeutics for cancer treatment | - | - | 24/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Aavocyte's competitors? Click here to see the top ones
Aavocyte's Investments and acquisitions
Aavocyte has made no investments or acquisitions yet.
Reports related to Aavocyte
Here is the latest report on Aavocyte's sector:
Are you a Founder ?
FAQs about Aavocyte
Explore our recently published companies
- KGP Forwarder - Iran based, 1994 founded, Unfunded company
- Pinnacle Text - Olympia based, 2019 founded, Unfunded company
- Wheel Wingman - Unfunded company
- Team Well Ross Realty - 2015 founded, Unfunded company
- bioSeedin - Cambridge based, 2019 founded, Unfunded company
- Highbury Associates - Seattle based, Unfunded company
